Neumirna Therapeutics ApS — Credit Rating and Financial Key Figures

Neumirna Therapeutics ApS (CVR number: 41696451) is a company from KØBENHAVN. The company recorded a gross profit of -5495.9 kDKK in 2024. The operating profit was -8290.4 kDKK, while net earnings were -6954.2 kDKK. The profitability of the company measured by Return on Assets (ROA) was -39.6 %, which can be considered poor and Return on Equity (ROE) was -118.3 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -77 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Neumirna Therapeutics ApS's liquidity measured by quick ratio was 0.2 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.